|
RBM12B expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.78546066820218E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.62403424042168E-12 |
| Normal-vs-Stage2 |
7.80000508626699E-11 |
| Normal-vs-Stage3 |
1.63247193540883E-12 |
| Normal-vs-Stage4 |
1.64823710235851E-12 |
| Stage1-vs-Stage2 |
6.750400E-01 |
| Stage1-vs-Stage3 |
2.466000E-02 |
| Stage1-vs-Stage4 |
3.470100E-02 |
| Stage2-vs-Stage3 |
2.493600E-01 |
| Stage2-vs-Stage4 |
1.747200E-01 |
| Stage3-vs-Stage4 |
6.991800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.74760206306246E-12 |
| Normal-vs-AfricanAmerican |
1.74557999998992E-05 |
| Normal-vs-Asian |
2.00810479356051E-11 |
| Caucasian-vs-AfricanAmerican |
1.480240E-01 |
| Caucasian-vs-Asian |
8.371600E-01 |
| AfricanAmerican-vs-Asian |
2.660600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
9.32587340685131E-14 |
| Normal-vs-Female |
2.78665979180914E-13 |
| Male-vs-Female |
4.706800E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.88147283811213E-12 |
| Normal-vs-Age(41-60Yrs) |
<1E-12 |
| Normal-vs-Age(61-80Yrs) |
1.2312373343093E-13 |
| Normal-vs-Age(81-100Yrs) |
7.78740000000333E-05 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
1.733210E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.590430E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
3.422400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
8.169200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
6.422200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
6.958000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.91968999999625E-05 |
| Classical-VS-Follicular |
2.454000E-01 |
| Classical-VS-Other |
4.622800E-01 |
| Classical-VS-Normal |
1.36249900251073E-11 |
| Tall-VS-Follicular |
7.519300E-03 |
| Tall-VS-Other |
4.229200E-01 |
| Tall-VS-Normal |
1.62503344114384E-12 |
| Follicular-VS-Other |
7.717600E-01 |
| Follicular-VS-Normal |
1.71918035363205E-12 |
| Other-VS-Normal |
5.789100E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.8034462812011E-12 |
| Normal-vs-N1 |
8.02824473566943E-12 |
| N0-vs-N1 |
8.262800E-01 |
|
|
